Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians seeking to improve human health, today announced the appointment of diagnostics industry veterans John Palma, PhD, and Don Hardison to its Board of Directors. In addition to Dr. Palma and Mr. Hardison, the Arima Genomics Board of Directors consists of Elizabeth Brady, Siddarth Selvaraj, and Xin Huang.
“3D genomics is proving to be an increasingly important tool for discerning clinically actionable information for improving human health and disease, especially in cancer,” said Siddarth Selvaraj, PhD., Chief Executive Officer at Arima Genomics. “John and Don bring a wealth of operational expertise in cancer diagnostics. With their guidance, we can fully realize the promise of matching every patient to the right targeted therapy.”
John Palma is Vice President of Global Medical Affairs at Agilent Technologies, Inc. and brings over 29 years of experience in developing, managing, and delivering complex diagnostics and research products. Over his career, he has consulted with global clinical colleagues and key opinion leaders on advancing high medical value companion diagnostics across the pathology and molecular laboratory customer segments. In addition, John brings deep experience in clinical studies, health outcomes research, product development, and management, having held leadership roles at Agilent, Roche, and Veridex (as a Johnson & Johnson company).
“Despite remarkable advancements in cancer diagnostics and therapies over the past decade, diagnostic tools need further discovery and development to yield actionable answers for many patients,” said John Palma. “Arima Genomics has identified an exciting new way to unlock new diagnostic possibilities which could benefit patients with cancer and a range of conditions in the coming years.”
Don Hardison has extensive industry leadership experience in executive positions as President and Chief Executive Officer of Biotheranostics, Inc. (now a Hologic company), Good Start Genetics, Inc., and Exact Sciences Corporation, as well as a wide range of experience in the clinical diagnostics field with LabCorp, Quest Diagnostics, and SmithKline Corporation (now GSK). In addition to Arima Genomics, he sits on the boards of BioPorto, Cytek Biosciences, HTG Molecular, and MDXHealth.
“There is a revolution in diagnostics whereby a range of new technologies is radically transforming old ways of doing things. Old players are being displaced by emerging companies like Arima Genomics, with novel approaches to answering previously unanswerable questions,” said Don Hardison. “There remains a tremendous opportunity to leverage Arima Genomics’ 3D genomics-based solutions towards new research, translational, and clinical applications.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
